Literature DB >> 3663465

Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer.

D J Crawford1, S Cowan, R Fitch, D C Smith, R E Leake.   

Abstract

Sequential biopsies of breast cancer tissue were obtained from a total of 210 women in order to assess any change in oestrogen receptor (ER) status arising spontaneously or as a result of intervening therapy. A combined assay measuring both cytosol and nuclear oestrogen receptors was used for all samples. One hundred and fifty-five patients had biopsies of their primary tumour and of a later loco-regional recurrence; 26 had biopsies of their primary tumour and a recurrence or new primary in the opposite breast; and 29 had sequential biopsies of recurrent disease only. Overall only 61.2% of the primary tumours retained their original status with respect to both cytosol and nuclear oestrogen receptors on recurrence. These results were influenced by intervening therapy, however, and if only untreated patients are considered, over 70% of their recurrences contain the same combination of cytosol and nuclear receptors as found in the primary tumours. For tumours 'recurring' in the opposite breast, the pattern was similar with 69.2% retaining the same status as the first primary. The agent found most likely to alter I:R status was tamoxifen and in the samples taken from patients undergoing treatment with this drug, no tumour was found to contain measurable receptor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663465      PMCID: PMC2002150          DOI: 10.1038/bjc.1987.171

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer.

Authors:  P P Rosen; C J Menendez-Botet; J A Urban; A Fracchia; M K Schwartz
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

3.  Distribution of the oestrogen-induced protein and of total protein between endometrial and myometrial fractions of the immature and mature rat uterus.

Authors:  B S Katzenellenbogen; R E Leake
Journal:  J Endocrinol       Date:  1974-12       Impact factor: 4.286

4.  Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma.

Authors:  C Silfverswärd; L Skoog; S Humla; S A Gustafsson; B Nordenskjöld
Journal:  Eur J Cancer       Date:  1980-01       Impact factor: 9.162

5.  Changes in multiple or sequential estrogen receptor determinations in breast cancer.

Authors:  J C Allegra; A Barlock; K K Huff; M E Lippman
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

6.  Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy.

Authors:  F C Campbell; R W Blamey; C W Elston; A H Morris; R I Nicholson; K Griffiths; J L Haybittle
Journal:  Lancet       Date:  1981-12-12       Impact factor: 79.321

7.  Variation in receptor status between primary and metastatic breast cancer.

Authors:  I M Holdaway; J V Bowditch
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

8.  Human breast cancer: heterogeneity of estrogen binding sites.

Authors:  H S Poulsen; J Jensen; C Hermansen
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

9.  Multiple simultaneous and sequential estrogen receptor values in patients with breast cancer.

Authors:  M E Peetz; D L Nunley; H S Moseley; E J Keenan; C E Davenport; W S Fletcher
Journal:  Am J Surg       Date:  1982-05       Impact factor: 2.565

10.  Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.

Authors:  R E Leake; L Laing; K C Calman; F R Macbeth; D Crawford; D C Smith
Journal:  Br J Cancer       Date:  1981-01       Impact factor: 7.640

View more
  5 in total

1.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.

Authors:  C A Encarnación; D R Ciocca; W L McGuire; G M Clark; S A Fuqua; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  The prognosis of breast cancer patients in relation to the oestrogen receptor status of both primary disease and involved nodes.

Authors:  L Castagnetta; A Traina; G Carruba; E Fecarotta; G Palazzotto; R Leake
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

3.  Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.

Authors:  R L Balleine; M J Earl; M L Greenberg; C L Clarke
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.

Authors:  S Nicholson; P Halcrow; J R Sainsbury; B Angus; P Chambers; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

5.  Change in the oestrogen receptor status of breast cancer with age--comparison of two types of assay.

Authors:  D J Gaskell; K Sangster; A L Tesdale; D Carson; R A Hawkins
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.